Krish Patel, MD is a clinical investigator, Director of the Lymphoma Program, and Director of Hematologic Malignancies and Cellular Therapy at the Swedish Cancer Institute (SCI) in Seattle, Washington. Dr. Patel completed his medical school, residency, and hematology and oncology fellowship training at Duke University School of Medicine where he served as a Chief Resident in Internal Medicine. In 2016, he joined the Swedish Cancer Institute, Center for Blood Disorders and Cellular Therapy as a specialist in the care of patients with lymphomas and CLL. In 2019, he was appointed as the Director of the Lymphoma Program at SCI to help continued development of the program’s clinical standards for lymphoma care, assist in the programmatic expansion of cell therapy services, and to help shape the continued growth of the lymphoma program’s clinical research endeavors.

In early 2022, Dr. Patel was named the Director of Hematologic Malignancies and Cellular Therapy to oversee the continued growth of SCI’s clinical and research programs in all hematologic diseases and broader strategy in growth of cell therapy, including applications of cellular therapy in solid tumor malignancies.

Clinically, Dr. Patel specializes in all aspects of care of patients with lymphomas and CLL and is a specialist in the therapeutic use of cellular and non-cellular immunotherapies. He has a specific research focus in the early stage development of novel targeted agents, immunotherapies, and engineered cellular therapies to advance care for patients with lymphoid malignancies. He is a principal investigator for numerous therapeutic clinical trials at SCI, with a focus on phase I and II studies in lymphomas, CLL, and cellular therapies. Dr. Patel is also a member of the Paul G. Allen Research Center at SCI, serving as a co-founding member of the Center for Immuno-oncology.